T
TriNetX
Combines real-time access to longitudinal clinical data with state-of-the-art analytics
About TriNetX
TriNetX operates as a global health research network that optimizes clinical research and enables discoveries through the generation of real world evidence (RWE). The company serves healthcare organizations, pharmaceutical companies, and researchers by providing real-time access to clinical data from the largest global network of healthcare organizations. TriNetX operates in the healthcare and life sciences market, focusing on improving the efficiency and effectiveness of clinical trials and observational research studies.
The business model revolves around offering a data-driven approach to clinical trial design and feasibility processes, allowing clients to quickly gain insights into patient treatments and outcomes. TriNetX makes money through subscriptions to its data and analytics platform, as well as through partnerships and collaborations with healthcare organizations and pharmaceutical companies.
TriNetX is committed to community involvement and the democratization of software tools, as evidenced by their open source contributions like the OPS to SNOMED CT Mapping solution. The platform supports region-specific studies compliant with local privacy regulations in over 25 countries, making it a versatile tool for global research.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2013
- Headquarters
- Cambridge, United States
- Employees
- 277
- Open positions
- 11
- Dealroom signal
- 66.1/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Analytics, Spinout, Hospital, Arts & Culture, Tech for Biotech and Pharma, Hard Tech, DT and LS, science-based
- Technology
- Big Data, Deep Tech
- Business model
- SaaS
- Client focus
- b2b
- Investment activity
- 1 company, latest Jan 2022
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| BUYOUTOther financing | Sep 2020 | $0 | — | The Carlyle Group | — |
| SERIES DOther financing | Mar 2019 | $40M | $160M | Itochu Technology Ventures · Mitsui Global Investment · F2 Ventures · MPM BioImpact | ↗ |
Growth signals
Latest recorded traffic for TriNetX is 200K monthly website visits, up 42.9% over the last three months. TriNetX's team declined 4.2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 CerenionMedical device company providing AI-based software for monitoring of brain function in intensive care |
Oulu, Finland | Operational | 20 | $11M | $19M |
 NBT AnalyticsEEG analysis for clinical trials |
Amsterdam, Netherlands | Operational | |||
 IcometrixAI-powered software for quantitative brain scan analysis |
Leuven, Belgium | Acquired | |||
 PepticomAn Artificial Intelligence (AI) company for the discovery of novel molecules in the Pharmaceutical and Agricultural markets |
Jerusalem, Israel | Operational | |||
 Blackford AnalysisAlgorithmic solutions to problems requiring real-time analysis of datasets |
Edinburgh, United Kingdom | Acquired | |||
 Pieces TechSoftware which interprets patient data in real time |
Irving, United States | Acquired | |||
 Aiforia TechnologiesAI-powered pathology image analysis software for researchers |
Helsinki, Finland | Operational | |||
 CongenicaClinical genomics analytics platform |
Hinxton, United Kingdom | Acquired |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
MPM BioImpact
Deerfield- FVF2 Ventures
Series B and later4 investors entered at this stage
Merck Global Health Innovation Fund
Itochu Technology Ventures
Mitsui Global Investment
The Carlyle Group
Other known investors1 additional known investor
Ghent University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about TriNetX on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TriNetX’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.